Cancer Leadership Council
Home  |  Sitemap  |  Contact Info
About CLCWhat's NewPolicy IssuesParticipants' Login

Clinical Trials—Medicare  |  Clinical Trials—Private Insurance  |  Medicare Payment
FDA  |  Cancer Research  |  Stem Cell Research
Policy Issues
Clinical Trials--Private Insurance

PDF version Printer-friendly

CLC Endorses Access to Cancer Clinical Trials Act
June 25, 2008

June 25, 2008

Dear Senator/Representative:

The undersigned organizations are cancer patient advocates, providers and researchers, known collectively as the Cancer Leadership Council. We write to urge your support for the Access to Cancer Clinical Trials Act (H.R. 2676/S. 2999).

The Access to Cancer Clinical Trials Act would address a serious shortcoming in insurance coverage for cancer patients by amending the Employee Retirement Income Security Act of 1974 (ERISA), the Public Health Service Act, and the Internal Revenue Code to prohibit health plans from denying covered cancer patients the opportunity to participate in high quality clinical trials. For many cancer patients, enrollment in a clinical trial may offer the best prospect for a favorable outcome, yet many insurers disallow participation in clinical trials as “experimental.” Removing economic barriers to clinical trials participation is also necessary to ensure that accrual to trials is not slowed and with it the pace of research on new therapies.

Our organizations have urged state legislatures to require coverage of treatment in a cancer clinical trial, and a number of states have in fact adopted such legislation. However, the effect of ERISA is to exempt self-funded insurance plans from state regulation, thus negating the impact of the state legislative measures for many cancer patients. The Access to Cancer Clinical Trials Act would not only overcome this limitation imposed by ERISA but would also go further to require coverage of cancer clinical trials by private insurance plans even in the absence of state legislation.

Since 2000 the Medicare program has provided coverage of clinical trial treatment, and the experience there has demonstrated that such coverage is feasible, inexpensive and likely to encourage participation in clinical trials that are essential for continued progress against cancer. We strongly believe that H.R. 2676/S. 2999 will achieve similar positive results for private insurance plans, and we offer our endorsement.


American Cancer Society Cancer Action Network
American Psychosocial Oncology Society
American Society of Clinical Oncology
Bladder Cancer Advocacy Network
Breast Cancer Network of Strength
C3: Colorectal Cancer Coalition
Cancer Care
The Children's Cause for Cancer Advocacy
Coalition of Cancer Cooperative Groups
Gilda's Club Worldwide
International Myeloma Foundation
Kidney Cancer Association
Lance Armstrong Foundation
The Leukemia & Lymphoma Society
Lung Cancer Alliance
Lymphoma Research Foundation
National Coalition for Cancer Survivorship
National Lung Cancer Partnership
National Patient Advocate Foundation
North American Brain Tumor Coalition
Pancreatic Cancer Action Network
Prevent Cancer Foundation
Sarcoma Foundation of America
Susan G. Komen for the Cure Advocacy Alliance
Us Too International Prostate Cancer Education and Support Network
The Wellness Community

Back to Clinical Trials—Private Insurance Index


About CLC  |  What's New  |  Policy Issues  |  Participants' Login
Home  |  Sitemap  |  Contact Info

Copyright © 2001-2002 Cancer Leadership Council. All rights reserved.
Please send comments and suggestions to